European Society for Medical Oncology (ESMO)

Phase 1 results of the prospective, open-label, uncontrolled, multicenter, phase 1/2 LUPER study (NCT04358237) indicated that the lurbinectedin plus the anti–PD-1 pembrolizumab combination regimen showed promising antitumor activity with a manageable safety profile in patients with relapsed small cell lung cancer (SCLC) and established the recommended phase 2 dose (RP2D) of lurbinectedin + pembrolizumab. Read More ›

Extensive-stage small cell lung cancer (ES-SCLC) is often treated with a combination of immunotherapy and chemotherapy; however, limited treatment options are available following progression on this combination regimen, underscoring the need for novel therapies in the second-line setting. Read More ›

The randomized, placebo-controlled, phase 3 EXTENTORCH trial (NCT04012606) assessed the clinical efficacy and safety of the anti–PD-1 antibody toripalimab in combination with etoposide plus platinum-based chemotherapy for the first-line treatment of patients with extended-stage SCLC (ES-SCLC); initial results of this study, presented at the 2023 ESMO annual meeting, are summarized here. Read More ›

New immunotherapeutic approaches are being investigated in small cell lung cancer (SCLC). Tarlatamab is a bispecific T-cell engager that binds to both delta-like ligand 3 (DLL3) on SCLC cells and CD3 on T cells to elicit T-cell–mediated tumor lysis. Read More ›

A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks. Read More ›

The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin. Read More ›

A phase 2, randomized study of patients with platinum-resistant relapsed ovarian cancer assessed overall response to olaparib monotherapy compared with standard-of-care chemotherapy. Olaparib was effective in platinum-resistant and platinum-sensitive patients with and without homologous recombination repair (HRR) gene alterations. Read More ›

An observational study of hospitalized patients and patients in outpatient treatment facilities being treated with olaparib as maintenance therapy for relapsed BRCA-mutated ovarian cancer following platinum-based chemotherapy reveals preservation of health-related quality of life in interim study results. Read More ›